Hahn: FDA Weighs Whether Some COVID-19 Policies Could Be Extended

By Beth Wang / June 1, 2020 at 5:56 PM
FDA chief Stephen Hahn has asked agency officials to look into whether some of the more flexible and novel approaches FDA has taken to respond to COVID-19, including allowing remote clinical trial visits, using real-world evidence to make certain regulatory decisions and streamlining lab test approvals, could be applied more broadly and on a more permanent basis. “I think the entire FDA team has now seen firsthand that we need to take a critical look at some of our processes...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.